Welcome to our dedicated page for Ocular Therapeut news (Ticker: OCUL), a resource for investors and traders seeking the latest updates and insights on Ocular Therapeut stock.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) generates frequent news as an ophthalmology-focused biopharmaceutical company advancing late-stage retinal programs and a commercial eye-care product. Its press releases highlight progress across the AXPAXLI (OTX-TKI) clinical programs in wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR), as well as updates related to DEXTENZA, financings, and corporate events.
News coverage for OCUL commonly includes clinical milestones such as target randomization in the SOL-R Phase 3 wet AMD trial, completion of randomization in SOL-1, and the initiation or advancement of the HELIOS Phase 3 registrational program in NPDR. The company also issues announcements about regulatory strategy, including Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration for SOL-1 and HELIOS-2 and plans to leverage the 505(b)(2) pathway for AXPAXLI in wet AMD.
Investors following OCUL news will see regular business and capital markets updates, such as underwritten equity offerings, cash runway disclosures, and inducement equity grants under Nasdaq Listing Rule 5635(c)(4). The company also reports quarterly financial results and business highlights, describing clinical execution, trial timelines, and planned extension studies like SOL-X for long-term evaluation of AXPAXLI in wet AMD.
In addition, Ocular Therapeutix announces participation in scientific and investor conferences, where it presents data from earlier-stage trials (for example, HELIOS Phase 1 results in NPDR) and discusses its strategy to "redefine the retina experience." For a consolidated view of these developments, the OCUL news page on Stock Titan brings together clinical, regulatory, financial, and corporate communications so readers can track how trial outcomes, regulatory interactions, and financing activities may shape the company’s ophthalmic pipeline and commercial portfolio over time.
Ocular Therapeutix (NASDAQ: OCUL) reported Q1 2026 results and program milestones on May 5, 2026. Key clinical highlights include positive Phase 3 SOL-1 superiority results for AXPAXLI in wet AMD (p=0.0006) and initiation of the SOL-X extension. Cash was $666.7 million as of March 31, 2026, with expected runway into 2028.
The company plans an NDA submission for AXPAXLI based on SOL-1 Week 52 data, subject to FDA discussions, and will host Investor Day on June 17, 2026.
Ocular Therapeutix (NASDAQ: OCUL) announced enrollment of the first patient in SOL-X, a three-year open-label long-term extension trial of AXPAXLI (OTX-TKI) for wet age-related macular degeneration (wet AMD).
SOL-X invites subjects who completed two-year follow-up in SOL-1 or SOL-R to assess long-term safety, sustained VEGF suppression, reduced treatment burden, and potential to improve long-term visual outcomes.
Ocular Therapeutix (NASDAQ: OCUL) will report first-quarter 2026 financial results and host a live conference call and webcast on May 5, 2026 at 8:00 AM ET. The company will discuss business progress and results for the quarter ended March 31, 2026. A replay will be archived for at least 30 days.
Ocular Therapeutix (NASDAQ: OCUL) will participate in multiple scientific and investor conferences in May 2026, including Bank of America Health Care Conference (May 12), Stifel Virtual Ophthalmology Forum (May 26), ARVO (May 1–7) and Retina World Congress (May 14–17), plus the Royal College of Ophthalmologists congress (May 18–20).
Key presentations cover Phase 3 OTX-TKI SOL-1 results, TKI program updates, real-world anti-VEGF analyses, and company fireside chats. Webcasts will be available via the company investor relations Events and Presentations page, with replays archived for at least 30 days.
Ocular Therapeutix (NASDAQ: OCUL) will host an Investor Day in New York City on Wednesday, June 17, 2026, beginning at 2:00 PM ET, with virtual access and a live webcast. Senior leadership and retinal disease key opinion leaders will participate. A replay will be archived for at least 30 days.
Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards under its 2019 Inducement Stock Incentive Plan to six newly hired non-executive employees (effective April 8, 2026) and to Jerome M. Gangitano, SVP, CMC Technical Operations (effective April 13, 2026).
The non-executive awards total options for 46,425 shares and RSUs for 15,275 shares with an $8.42 exercise price. Mr. Gangitano received options for 300,000 shares and RSUs for 100,000 shares with an $8.86 exercise price. Options have ten-year terms; vesting schedules are four years for options and three years for RSUs.
Ocular Therapeutix (NASDAQ: OCUL) reported additional Week 52 SOL-1 Phase 3 post-hoc analyses for AXPAXLI in wet AMD showing unmatched durability and sustained anatomic and visual control versus aflibercept.
Key data: median time to ≥30 uM CSFT increase was 39 weeks vs 16 weeks; median time to ≥75 uM was 46 weeks vs 24 weeks. Company plans NDA submission based on SOL-1 alone, subject to formal FDA discussions.
Ocular Therapeutix (NASDAQ: OCUL) will present additional data and analyses from the SOL-1 Phase 3 superiority trial of AXPAXLI (OTX-TKI) at multiple scientific conferences in April 2026.
Presentations occur at the Vit-Buckle Society meeting in Las Vegas on April 11 and at CNO 2026 in Buenos Aires on April 15, with a VBS slide copy to be posted on Ocular’s website after April 11.
Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to three newly hired non-executive employees under its 2019 Inducement Stock Incentive Plan, effective March 6, 2026.
The awards comprise non-statutory stock options for an aggregate of 60,175 shares and restricted stock units for 19,975 shares. Options carry a $10.27 exercise price, a ten-year term, and a four-year vesting schedule; RSUs vest over three years with the first installment on March 6, 2027.
Ocular Therapeutix (NASDAQ: OCUL) will participate in multiple investor conferences in March 2026, including TD Cowen (March 2), Jefferies Biotech on the Beach (March 10), Citizens Life Sciences and Barclays (March 11) and RBC Ophthalmology (March 24).
Pravin U. Dugel, MD, Executive Chairman, President and CEO, will deliver several fireside chats. Live webcasts of TD Cowen, Citizens and RBC presentations will be available on the Investor Relations Events and Presentations page, with replays archived for at least 30 days.